Third-Party Allotment under Rehabilitation Plan... Existing Shareholders Diluted by 73%... Change of Control and Fundraising
EDGC has decided on a third-party allotment capital increase under the court-approved rehabilitation plan, issuing 165,000,000 new shares (face value KRW 100) to raise a total of KRW 16.5 billion.
The total outstanding shares before the increase are 60,531,114 (after stock merger and cancellation), and after issuance, total shares will increase to 225,531,114, resulting in existing shareholders' stake being diluted to approximately 26.8%.
The third-party allottees are Haemiri (110,000,000 shares) and AIT Story (55,000,000 shares), who are M&A acquirers expected to take over management control.
The new share issuance price is KRW 100, a discount of approximately 76% compared to the last closing price of KRW 415 before trading suspension, issued at par value due to the rehabilitation process.
The funds will be used for rehabilitation claim repayment and operating expenses; the listing date is scheduled for June 2, 2026 (delayed from June 1).
The allottees are subject to a six-month lock-up from the listing date, limiting short-term selling pressure.
[AI Comprehensive Analysis]This capital increase is part of the rehabilitation process, causing severe dilution for existing shareholders and transferring control to new investors. While it may negatively impact share price in the short term, successful rehabilitation could lead to enterprise value recovery; investors should approach with caution.
KOSDAQ Filing Information
Filing: [Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)
Company: Eone Diagnomics Genome Center (245620)
Submission: Eone Diagnomics Genome Center Co., Ltd.